ArticleViruses2018
Recombinant GII.P16/GII.4 Sydney 2012 Was the Dominant Norovirus Identified in Australia and New Zealand in 2017.
Article in Viruses, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 54 citations in OpenAlex.
- Emergence and predominance of GII.17[P17] noroviruses in Brazil, 2023-2024.Scientific reports · 2026Article
- Clinical, Molecular and Evolutionary Characterization of Noroviruses in Hospitalized Children With Acute Gastroenteritis in Vietnam, 2016 to 2021.Journal of medical virology · 2026Article
- The increased detection of recombinant norovirus GII.4 Sydney_2012[P16] strains in hospitalized pediatric patients with gastroenteritis in Shanghai, China.BMC infectious diseases · 2026Article
- A Decade of Chronic Norovirus Infection Surveillance at the National Institutes of Health Clinical Research Center: Clinical Characteristics, Molecular Epidemiology, and Replication.The Journal of infectious diseases · 2025Article
- A new wave of resurgence for GII.4 Sydney in Huzhou, particularly GII.4 Sydney[P16], between 2019 and 2023.BMC infectious diseases · 2025Article
- Foodborne acute gastroenteritis outbreak associated with a rare norovirus recombinant GII.10[P16] genotype, Brazil, 2023.Memorias do Instituto Oswaldo Cruz · 2025Article
- Genetic diversity of norovirus in Shenzhen Based on continuous surveillance from 2016 to 2022.Frontiers in cellular and infection microbiology · 2025Article
- Article
- Epidemiological Features of Human Norovirus Genotypes before and after COVID-19 Countermeasures in Osaka, Japan.Viruses · 2024Article
- Norovirus Epidemiology and Genotype Circulation during the COVID-19 Pandemic in Brazil, 2019-2022.Pathogens (Basel, Switzerland) · 2023Article
- Changing predominance of norovirus strains in children with acute gastroenteritis in Shanghai, 2018-2021.Virologica Sinica · 2023Article
- Emergence of GII.4 Sydney[P16]-like Norovirus-Associated Gastroenteritis, China, 2020-2022.Emerging infectious diseases · 2023Article
- Epidemiology and genetic diversity of norovirus GII genogroups among children in Hubei, China, 2017-2019.Virologica Sinica · 2023Article
- Molecular epidemiology analysis of symptomatic and asymptomatic norovirus infections in Chinese infants.Virology journal · 2023Article
- Recent insights into reverse genetics of norovirus.Virus research · 2023Review
- Feasibility of Polyclonal Avian Immunoglobulins (IgY) as Prophylaxis against Human Norovirus Infection.Viruses · 2022Article
- Epidemiological and Genetic Characterization of Norovirus Outbreaks That Occurred in Catalonia, Spain, 2017-2019.Viruses · 2022Article
- Article
- Evolutionary analyses of emerging GII.2[P16] and GII.4 Sydney [P16] noroviruses.Virus evolution · 2022Article
- Epidemiology and evolution of Norovirus in China.Human vaccines & immunotherapeutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For the past two decades, norovirus pandemic variants have emerged every 3⁻5 years, and dominate until they are replaced by alternate strains. However, this scenario changed in 2016 with the co-circulation of six prevalent viruses, three of which possessed the pandemic GII.4 Sydney 2012 capsid. An increased number of institutional gastroenteritis outbreaks were reported within the Oceania region in mid-2017. This study identified emerging noroviruses circulating in Australia and New Zealand in 2017 to assess the changing dynamics of the virus infection. RT-PCR-based methods, next generation sequencing, and phylogenetic analyses were used to genotype noroviruses from both clinical and wastewater samples. Antigenic changes were observed between the capsid of pandemic Sydney 2012 variant and the two new Sydney recombinant viruses. The combination of these antigenic changes and the acquisition of a new ORF1 through recombination could both facilitate their ongoing persistence in the population. Overall, an increased prevalence of GII.P16/GII.4 Sydney 2012 viruses was observed in 2017, replacing the GII.P16/GII.2 recombinant that dominated in the region at the end of 2016. This shift in strain dominance was also observed in wastewater samples, demonstrating the reliability of wastewater as a molecular surveillance tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.